Pfizer Gives $897 Million In Manufacturing Deals To Samsung Biologics
Tuesday saw the announcement of two contracts worth a combined $897 million by Samsung Biologics, a South Korean company, to produce goods for Pfizer. As a result of the most recent agreements, the Samsung Group’s biotech division will create biosimilar goods in South Korea at its new Plant 4 up until 2029, covering everything from…









